| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2154511 | Nuclear Medicine and Biology | 2008 | 14 Pages |
Abstract
Treatment with 131I-MIBG can be considered for patients if surgery is not feasible. There are significant risks associated with this treatment, but the majority of patients will respond. Treatment with 131I-MIBG should be done at institutions with experience in delivering targeted radiotherapeutics.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
![Meta[131I]iodobenzylguanidine therapy for patients with metastatic and unresectable pheochromocytoma and paraganglioma](/preview/png/2154511.png "First Page Preview: Meta[131I]iodobenzylguanidine therapy for patients with metastatic and unresectable pheochromocytoma and paraganglioma")
Authors
Robert E. Goldsby, Paul A. Fitzgerald,